Originally published by our sister publication Clinical Oncology News
By Clinical Oncology News Staff
The FDA has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, Bristol Myers Squibb) for adult and pediatric patients 12 years of age and older with unresectable or metastatic microsatellite instability−high (MSI-H) or mismatch repair−deficient (dMMR) colorectal cancer (CRC). The FDA also converted the accelerated approval to regular approval for single-agent